Philips Healthcare’s Moneshia zu Eltz discusses future of digital health at
OurCrowd’s Global Investor Summit 2016

“This quote needs to counter any objections people might have using the product.”

JOHN SMITH

Highlight The Features

Add some more descriptive content here to define your feature offering and how it contributes to the overall experience.

Feature One

Clearly outline this features importance and relevance.

Feature Two

Feature Three

Clearly outline this features importance and relevance.

Feature Four

Clearly outline this features importance and relevance.

What People Are Saying About Voyage

“This quote needs to nudge people toward a conversion by establishing trust.”

JANE SMITH

A very clear closing argument statement of your offer.

Zu Eltz describes Philips Healthcare’s
Partnership & Collaboration Model

Your ultra-diversified startup portfolio with a single investment.

OurCrowd Portfolio Companies shaping the future of digital health

Sweetch is a smartphone platform that leverages a unique diabetes prediction engine to produce a dynamic risk-meter, which interfaces with a custom, automated coaching regimen to guide users toward lowering their risk of developing diabetes in compliance with the “Diabetes Prevention Program” (DPP).

www.sweetch.com

Sight Diagnostics is pioneering an innovative computer vision platform for cheaper, faster, and fully-automated blood diagnostics whose first application is the 300 million annual tests for Malaria worldwide. The Sight Diagnostics platform combines computer vision with patented blood-preparation techniques to count blood cells and differentiate between healthy and parasite-infected blood.
www.sightdx.com

Yossi Bahagon, Chairman, Sweetch

Seth Salpeter, Chief Science Officer, Sight Diagnostics

Featured Content

Changing the Landscape of MedTech Investing
Duis fringilla quam a libero convallis, a lacinia metus tempus. Donec vel erat dolor. Quisque sed cursus eros.
READ MORE

OurCrowd’s MedTech Portfolio

Since its inception in 2013, OurCrowd and its investor community have made 91 investments totaling $200 million and ~20% of the investments made have been in medical devices, healthcare, and big data for the medical industry.

Innovative technology bringing lung-function testing to the desktop

$1.4M

FUNDED

Patient-specific 3D imaging for planning and rehearsing complex surgeries

$1.7M

FUNDED

OurCrowd has more than 75 other companies in its portfolio,
in e-commerce, IoT, AutoTech, AgTech, Cybersecurity, VR, Real Estate Tech, Social, and Enterprise Software

As Featured In:

Team

Dr. Morris Laster
OurCrowd Venture Partner
20 yrs of experience in biopharmaceuticals
Founder of 6 companies that have gone public in the US, UK and Israel

S. Morry Blumenfeld
Head of OurCrowd’s Medical Advisory Board
President and CEO of Quescon Consultants Former executive at GE for ~35 years Initiated CT and MRI business at GE Medical Systems.

Norbert Pelc, PhD, Sc.D.
Advisor
Boston Scientific Applied Biomedical Engineering Professor Stanford University Chair Bioengineering

Dr. Ziv Haskal, FSIR FAHA FACR
Advisor
Top Endovascular Specialist and Interventional Radiology expert Professor of Radiology, University of Virginia School of Medicine Editor-in-chief, Journal of Interventional and Vascular Radiology

Reuben Mezrich, PhD, MD, FACR
Advisor
Professor and former chair of the Departmniversity of Maryland School of Medicine

Dr. Zev Davis, M.D.
Advisor
Serves as Director of Cardiovascular Surgery of the Edward Heart Hospital in Naperville, Illinois. Dr. Davis serves as a partner in Cardiac Surgery Associates.

OurCrowd’s investment ecosystem includes a medical Venture Partner and a Medical Advisory Board, who advise, guide, and serve as board members for our MedTech portfolio. OurCrowd’s Medical Advisory Board includes:

OurCrowd's professional team is comprised of entrepreneurs, venture capitalists, investors, and geeks with decades of combined experience building businesses, raising capital, and investing in Israeli and global startups. OurCrowd’s leadership includes:

Pairing OurCrowd's investment efficiency, control, independence and dynamic early stage deal orgination with strategic and prominent venture capital firms, global corporate partners, private equity, angel groups and super-angels.

Corporate, Institutional, and Venture Capital Co-Investors include:

Co-Investors

Israel: The Ideal Ecosystem for MedTech Investing

Diversification across a broad group of investments is an absolute must when building a successful portfolio. How can you gain access to such diversification?

The opportunity is open to you: build a highly-diversified portfolio of 50 startups with one investment starting at $50K.

OC50 Portfolio Index Fund is a new fund from OurCrowd, designed to give investors broad exposure to early and growth stage companies across a wide array of industries

$200M

TOTAL
RAISED

91

COMPANIES
FUNDED

4,000

COMPANIES
VETTED

11,000

ACCREDITED
INVESTORS

110

COUNTRIES
REPRESENTED

Robotic vision system for laparoscopic surgery

$1.8M

FUNDED

Bringing computer vision to the multibillion dollar blood testing industry

$1.5M

FUNDED

Wearable sensor & advanced analytics tracking Parkinson's Disease symptoms

$1.2M

FUNDED

Next generation accelerators for proton-beam cancer therapy

$1.2M

FUNDED

Preventing prescription errors through Big Data

$1.3M

FUNDED

Leading medtech incubator

$1M

FUNDED

(SGX:TTGL)

Mapping and quantified neural communication for brain diagnostics

$2M

FUNDED

World's first medical-grade cannabis inhaler

$2.2M

FUNDED

Giving paraplegics the ability to stand, walk and climb

$3.9M

FUNDED

(NASDAQ:RWLK)

Providing unprecedented mobility in any environment

$1.7M

FUNDED

Teaching computers to read medical imaging files, one algorithm at a time

FUNDED

Seed Investment
via OCFirst

Providing patient and self-insured employers with a simple and trustworthy measure of medical quality

FUNDED

Seed Investment
via OCFirst

Zu Eltz describes Philips Healthcare’s Partnership & Collaboration Model:
“…Connecting the dots is really what this is about in terms of the future of healthcare… This [is] not a continuum that any one company is going to be able to own or drive. [Philips] is collaborating… with the best of breed and the best of suite, with Amazon, with Salesforce, and with innovators that can build the apps…”

“Healthcare is personal,” Zu Eltz affirmed as she addressed the audience of thousands of investors, “it’s about… our individual health, the health of friends and family, [and] people that we live with.” Following Zu Eltz’s opening statements, the panel of startups that presented (see below) continued in the light of Philips Healthcare’s universal and impactful investment theme of “the promise of healthcare for all and population health, as well ‘our individual health.”

“With technology we’re at the cusp of the promise of changing healthcare and the way that it’s practiced in the future.” –Monesha Zu Eltz, VP Strategic Alliance and Partnering at Philips

Learn more about how to become part of the MedTech investment landscape, and how to invest in game-changing startups through OurCrowd.

Access pre-vetted startup investment opportunities.

Perform self-guided investment research with curated diligence materials.

Invest alongside trusted venture capital and angel investors.

The first adaptive motion-interaction brain rehabilitation platform

FUNDED

Seed Investment
via OCFirst

How do I invest in
Healthcare Startups ?

Hand-picked startup investments

Medical Advisory Board

Core Leadership

Jonathan Medved
Founder and CEO
Jonathan Medved is according to the Washington Post, ”one of Israel’s leading high tech venture capitalists”. In the September, 2008 NY Times Supplement “Israel at 60” Medved was named one of the top 10 most influential Americans who have impacted Israel.

Elan Zivotofsky
Head of Investments
15 years’ experience in Israeli investing as Managing Partner at Prelude Israel, head of technology banking at Lehman Brothers Israel and tech research analyst for Goldman Sachs

Pini Lozowick
General Partner and Chief Investment Officer
Serial entrepreneur, angel investor and venture capitalist, Previously general partner at Alta Berkeley, Director of Marketing at Broadcom, Chairman of Provigent, and founder and GM of Verisense

David Stark
Partner, Investments
Previously investment analyst at Blackstone in Real Estate PE Group

Gadi Mazor
General Partner and CTO
Serial entrepreneur, founding three startups in character and voice recognition and wireless communications
Previously sat on RIM (Blackberry) advisory board, and served on the US Senate committee that defined the US public alert system

Shai Ben Tovim
Partner and Chief Product Officer
Previously Head of Product at Wonga.com, President of R&D and Corp VP of Strategy at Alvarion

Joel Maryles
Venture Partner and Chief Exit Officer
Previously established and managed the Israeli investment banking operations for Citigroup/Salomon Smith Barney and ran it for over a decade, completing 60+ successful transactions including IPOs, private placements, debt offerings and mergers and acquisitions

Janine Kutliroff
Chief Client Officer
Previously founder and CEO of Omek Interactive, acquired by Intel, CEO of IDT Global Israel

Accelerating Investment in Digital Health

Zebra Medical Vision is an Israeli startup whose machine vision technology enables healthcare providers to make diagnostic decisions faster, more accurately and for less money. Zebra is led by a founding team that includes Eyal Gura, who has sold startups to eBay, Getty Images and others, Elad Benjamin, who brings decades of executive experience at medical information management companies, and Eyal Toledano, who ran Samsung's Israel R&D operations.

Elad Benjamin, CEO Zebra Medical Vision

Sweetch is a smartphone platform that leverages a unique diabetes prediction engine to produce a dynamic risk-meter, which interfaces with a custom, automated coaching regimen to guide users toward lowering their risk of developing diabetes in compliance with the “Diabetes Prevention Program” (DPP).

Yossi Bahagon, Chairman, Sweetch

Sight Diagnostics is pioneering an innovative computer vision platform for cheaper, faster, and fully-automated blood diagnostics whose first application is the 300 million annual tests for Malaria worldwide. The Sight Diagnostics platform combines computer vision with patented blood-preparation techniques to count blood cells and differentiate between healthy and parasite-infected blood.

Philips' Head of Strategic Partnerships discusses working with startups

Since its inception in 2013, OurCrowd and its investor community have made 91 investments totaling $200 million -- and ~20% of the investments made have been in medical devices, healthcare, and big data for the medical industry.

Seth Salpeter, Chief Science Officer, Sight Diagnostics

Accelerating Investment in Digital Health: Philips' Head of Strategic Partnerships discusses working with startups

Predicting and Preventing Diabetes at Scale

Global startups that are building the tech that will power our future

Why OC50?

Be an investor in a company that enables more patients access to pioneering
proton beam cancer treatment

OC50 Strategy

Diversification allows investors to leverage unique aspects of the venture asset class as well as reduce downside risk & retain upside potential.

OurCrowd has invested across six geographies and into a diverse range of industries to establish a portfolio with broad exposure to early and growth stage technology startups.

OC50 benefits from OurCrowd's existing portfolio and from diversification across stage

The OC50 Index Fund will also have exposure to a roster of follow-on rounds OurCrowd participates in for its existing portfolio in which OurCrowd invests at least $1.5M, Check out OurCrowd's existing startup portfolio here.

OurCrowd’s dealflow and investment processes have allowed it to diversify across stages from pre-seed through late stage and even mezzanine / pre-IPO financing. This stage diversification affords potential for distributions throughout the lifetime of fund.

Why startups?

Today’s biggest returns are going to early investors in private companies, especially high-growth technology companies. As the below graph demonstrates, venture capital consistently outperforms the market on a 10-yr time horizon:

Private Market Returns: Value capture has overwhelmingly shifted from public to private markets, greatly benefitting those with access to private companies

Access: Highly vetted companies by a team of investment professionals, offering investors access to in demand startups usually reserved for well-connected Angels

Diversification: To mitigate the levels of risk associated with this asset class, building a strong diversified portfolio is a must. OC50 allows investors to do this with a single investment

Track Record: In just a few short years, the OurCrowd portfolio has produced 10 exits, including acquisitions by Intel, Oracle, and Viber, and three IPOs

SIGN UP

About

Learn more here.

OurCrowd is the world leader in equity crowdfunding. Our veteran team of investment professionals vets and selects opportunities, invests its own capital, and leverages a community of over 15,000 accredited investors to fund, support, and grow global technology startups. OurCrowd’s success is driven by collaboration with people from across the global startup ecosystem – the entrepreneurs who dream, the investors who believe, and the mentors, partners and team members who drive our goals forward.

$330M

TOTAL
RAISED

110

COMPANIES
FUNDED

$14.8

LARGEST
RAISE

16,500

ACCREDITED
INVESTORS

112

COUNTRIES
REPRESENTED

Introducing:

OC50’s diversification is driven by a wide array of sectors and geographies that OurCrowd is active in

Only available for OurCrowd registered users